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ORIGINAL ARTICLE
Background/Aims: Although increased serum uric acid (SUA) concentrations are commonly encountered in
patients with risk factors for coronary artery disease (CAD), the clinical value of SUA has not been established. 
Methods: The study group comprised 687 consecutive patients with suspected CAD who had undergone
coronary angiography. CAD was defined as stenosis ≥ 50% of the luminal diameter. CAD severity was
expressed as 1-, 2-, or 3-vessel disease. Metabolic syndrome (MS) was defined according to National
Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) criteria, and aortofemoral pulse wave
velocity (PWV) was obtained by arterial catheterization invasively.  
Results: In total, 395 patients had CAD. SUA was higher in patients with CAD as compared to those without
CAD (5.5 ± 1.0 vs. 5.2 ± 1.0 mg/dL, p = 0.004). In addition, SUA was significantly associated with the severity of
CAD (p = 0.002). However, after adjusting for significant confounding factors including age, diabetes, smoking,
cholesterol, MS, and PWV, SUA was not an independent risk factor for CAD (p = 0.151). Based on a subgroup
analysis, SUA was more closely associated with CAD in women than in men, and in the highest quartile (≥ 6.4
mg/dL) than in the first quartile (< 4.8 mg/dL); however, these results were not significant (p = 0.062, p = 0.075,
respectively). In a multivariate regression analysis, the most important determinant of SUA was MS (i.e., insulin
resistance syndrome), which is strongly associated with CAD. 
Conclusions: In patients with suspected CAD, SUA was not an independent risk factor for CAD and may be
merely a marker of insulin resistance. (Korean J Intern Med 2010;25:21-26)
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INTRODUCTION
Increased serum uric acid (SUA) levels are frequently
encountered in subjects with obesity, glucose intolerance
[1], renal disease [2], hyperlipidemia, atherosclerosis [3],
and hypertension (HTN) [4], which all play a causal role
in the pathogenesis of coronary artery disease (CAD).  The
clinical value of SUA for predicting CAD, however, is
uncertain.
Several cohort studies [5,6] on subjects with HTN have
revealed a significant association between SUA and future
cardiovascular (CV) events. Additionally, based on data
from the First National Health and Nutrition Examination
Survey (NHANES I) [7], increased SUA levels are inde-
pendently and significantly associated with ischemic heart
disease and CV mortality. In contrast, results of the
Framingham Heart Study [8] and Evans County Study
[9], which are extensively quoted epidemiologic exami-
nations, have shown that hyperuricemia cannot be
recognized as an independent CV risk factor. 
The pathophysiologic mechanisms underlying increased
SUA concentrations in atherosclerotic diseases appear to
be accounted for by insulin resistance [10], which is a
major characteristic of metabolic syndrome (MS) and is
strongly associated with CAD. Therefore, the objectives of
the present study were to clarify the inde-pendent clinicalvalue of SUA and identify determinants responsible for
modulating SUA in subjects with suspected CAD. 
METHODS
Study subjects
The study was retrospectively conducted with patients
admitted to the cardiology department in Korea University
Guro Hospital, Seoul, Korea, between March 2002 and
December 2005. We included 716 consecutive patients
who had undergone coronary angiography for the
diagnosis or exclusion of CAD. Twenty-nine patients that
met the following criteria were excluded: previous history
of taking diuretics for antihypertensive medication, acute
coronary syndrome, cardiomyopathy, valvular heart
disease more serious than mild, postcardiac surgery, atrial
fibrillation, aortic dissection, and renal insufficiency. A
total of 687 subjects gave written informed consent and
were enrolled in the study. 
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Table 1. Clinical characteristics of subjects with and without coronary artery disease
Parameters CAD No CAD p value
(n = 395) (n = 292)
Age, yr 62.7 ± 10.2 56.8 ± 9.6 < 0.001
Male 177 (44.8) 111 (38.0) 0.074
Cigarette smoking 114 (28.9) 68 (23.3) 0.102
Body mass index, kg/m
2 24.9 ± 3.6 24.7 ± 3.4 0.679
Waist-to-hip ratio 0.92 ± 0.06 0.90 ± 0.09 0.006
Diabetes mellitus 126 (31.9) 67 (22.9) 0.010
Metabolic syndrome 139 (35.2)  82 (28.1) 0.049
Hypertension 234 (59.2) 171 (58.6) 0.858
Systolic blood pressure, mmHg 158.6 ± 16.9 157.9 ± 17.0 0.773
Diastolic blood pressure, mmHg 98.9 ± 12.8 96.2 ± 11.3 0.112
Ejection fraction, % 63.7 ± 7.1 64.5 ± 6.5 0.717
Total cholesterol, mg/dL 189.2 ± 45.6 182.6 ± 32.4 0.073
HDL-C, mg/dL 45.7 ± 14.3 49.4 ± 14.2 0.098
Triglyceride, mg/dL 152.4 ± 82.5 129.1 ± 75.5 0.031
LDL-C, mg/dL 113.1 ± 39.9 106.7 ± 32.0 0.048
Serum creatinine, mg/dL 0.8 ± 0.3 0.8 ± 0.2 0.897
Serum uric acid, mg/dL 5.5 ± 1.0 5.2 ± 1.0 0.004
Calcium channel blockers 158 (40.0) 108 (37.0) 0.423
ACEIs or ARBs 162 (41.0) 111 (38.0) 0.427
β-blockers 86 (21.8) 52 (17.8) 0.200
Values are presented as mean ± SD or number (%) of patients. 
CAD, coronary artery disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ACEIs,
angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
Figure 1. Severity of coronary artery disease and serum uric
acid (Kruskal-Wallis ANOVA, p = 0.002). 
CAD, coronary artery disease; VD, vessel disease; CI, confidence
interval.Baseline measurements and definitions
Hemodynamic measurements and blood sampling,
including SUA, were performed with the patient in the
supine position after 30 minutes of rest. A diagnosis of
HTN was based on a systolic blood pressure of ≥ 140
mmHg or a diastolic blood pressure of ≥ 90 mmHg with
repeated measurements, or antihypertensive drug
therapy. Diabetes mellitus (DM) was defined as a fasting
blood glucose concentration ≥ 126 mg/dL or
antihyperglycemic drug treatment. Body mass index
(BMI) was calculated as the weight in kilograms divided
by the square of the height in meters. MS was defined
according to National Cholesterol Education Program-
Adult Treatment Panel III (NCEP-ATP III) criteria (≥ 3 of
the following abnormalities) [11]: waist circumference
greater than 102 cm in men and 88 cm in women, serum
triglyceride (TG) level of at least 150 mg/dL (1.69
mmol/L), high-density lipoprotein cholesterol (HDL-C)
level of less than 40 mg/dL (1.04 mmol/L) in men and 50
mg/dL (1.29 mmol/L) in women, blood pressure of at
least 130/85 mmHg, or serum glucose level of at least 110
mg/dL (6.1 mmol/L).
Coronary angiography
All patients underwent routine coronary angiography
using the Judkins technique with digitized coronary
angiography equipment (Philips, Eindhoven, Netherlands).
All coronary angiograms were visually assessed by at least
three experienced angiographers, and a consensus was
reached. For this study, we defined significant CAD as
minimal lumen diameter stenosis ≥ 50% on the angiogram.
The severity of CAD was expressed as 1-, 2-, or 3-vessel
disease. 
Statistical analysis
Values were expressed as the mean ± SD. Categorical
variables were compared using a chi-square test. Differences
in the mean values between the two groups were compared
using an unpaired t-test. A pvalue of < 0.05 was considered
statistically significant. The effects of classic risk factors
on SUA were analyzed using a multivariate regression
analysis with stepwise selection. A multiple logistic
regression analysis was used to identify independent risk
factors of CAD. Classic CV risk factors included in the
multivariate models were age, gender, BMI, DM, smoking,
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Table 2. Odds ratio of coronary artery disease according to prognostic variables
Variable Number of subjects CAD, n (%) Crude OR (95% CI) Adjusted OR (95% CI)
Age
≤ 59 yr 324 149 (46.0) 1.00 1.00
> 60 yr 363 246 (67.8) 2.88 (1.69 - 4.92)b 2.96 (1.62 - 5.42)b
Gender
Famale 399 218 (54.6) 1.00 1.00
Male 288 177 (61.5) 1.76 (1.34 - 3.32) 1.52 (1.08 - 2.89)
Diabetes
No 494 269 (54.5) 1.00 1.00
Yes 193 126 (65.3) 2.64 (1.37 - 5.07)b 2.09 (0.95 - 4.61)a
Hypertension
No 282 153 (54.3) 1.00 1.00
Yes 405 242 (59.8) 1.55 (0.90 - 2.68) 1.46 (0.76 - 2.82)
Matabolic syndrome
No 466 256 (54.9) 1.00 1.00
Yes 221 139 (62.9) 1.98 (0.96 - 4.38)a 1.65 (0.97 - 2.81)
Serum uric acid
Quartile 1 (2.6 - 4.7, mg/dL) 171 93 (54.4) 1.00 1.00
Quartile 2 (4.8 - 5.6, mg/dL) 172 94 (54.7) 1.25 (0.59 - 2.65) 0.56 (0.18 - 1.72)
Quartile 3 (5.7 - 6.3, mg/dL) 171 96 (56.1) 1.62 (1.22 - 5.60) 1.16 (0.37 - 3.57)
Quartile 4 (6.4 - 9.2, mg/dL) 173 112 (64.7) 2.42 (1.12 - 5.20)a 1.88 (0.91 - 3.84)
Adjusted for age, gender, diabetes, hypertension, and metabolic syndrome. 
CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.
ap < 0.05.
bp < 0.01.total cholesterol, pulse wave velocity (PWV), and MS. We
calculated the 95% confidence interval (CI) for each odds
ratio (OR) and all p values were two-tailed. Crude rates
were compared using a Pearson-Mantel-Haenszel test.
Statistical analyses were performed using the SPSS 11.0
(SPSS Inc., Chicago, IL, USA).  
RESULTS
Clinical characteristics
Table 1 represents clinical characteristics of the study
population. The sample comprised 288 men and 399
women, and 395 patients had CAD (57.5%). The mean age
of the participants was 59.3 ± 10.4 years old. Subjects who
had CAD were older than those who did not (62.7 ± 10.2
vs. 56.8 ± 9.6, p < 0.001). DM (31.9 vs. 22.9%, p = 0.01)
and MS (35.2 vs. 28.1%, p = 0.049) were more common
among subjects with CAD. Moreover, they had a higher
waist-to-hip ratio (p = 0.006), greater TG (p = 0.031),
low-density lipoprotein cholesterol (LDL-C, p = 0.048),
and PWV levels (p < 0.001), and increased SUA (5.5 ± 1.0
vs. 5.2 ± 1.0, p= 0.004). Gender, smoking, total cholesterol,
HDL-C, and blood pressure were not significantly
different between the two groups.  
Clinical value of SUA
When the severity of CAD was expressed as 1-, 2-, 3-
vessel disease, or no CAD, a significant association was
observed between the severity of CAD and serum uric acid
levels (p= 0.002, Fig. 1).
In a multivariate logistic regression analysis, however,
the significant independent risk factors of CAD were age
(p = 0.001), DM (p = 0.021), and PWV (p = 0.048). In
contrast, waist-to-hip ratio (p = 0.089), TG (p = 0.114),
LDL-C (p = 0.167), MS (p = 0.278), and SUA (p = 0.151)
were not significantly or independently related to CAD. 
In a sex-specific analysis, only two factors, age (p =
0.002) and DM (p = 0.045), were significantly associated
with CAD in men and women. However, a trend was
detected toward MS and SUA being independent risk
factors of CAD in women (p= 0.059, p= 0.062, respectively),
but not men (p= 0.423, p= 0.299, respectively). 
Results of the adjusted ORs are reported in Table 2.
After adjusting for age, gender, DM, HTN, and MS, SUA
in the highest quartile (≥ 6.4 mg/dL) showed an increased
risk for CAD (OR, 1.88; 95% CI, 0.91 to 3.84) as compared
with SUA in the first quartile (< 4.8 mg/dL); however, this
result was not significant (p= 0.075). 
In the stepwise multivariate regression analysis,
significant determinants responsible for modulating SUA
levels included MS (p< 0.001), DM (p= 0.018), and gender
(p = 0.039). In a sex-specific analysis, MS was the only
independent determinant of SUA levels in men (p =
0.001) and women (p= 0.039). 
DISCUSSION
In the present study, SUA was not an independent risk
factor of CAD after adjusting for potential confounding
variables. Subgroup analyses, however, showed that SUA
was more strongly associated with an increased risk of
CAD in women (p = 0.062) than in men (p = 0.299).
These findings are consistent with results of previous
studies [8,12,13]. In contrast, the Framingham Heart
Study [8] detected no association between SUA and CV
events after adjusting for age, office blood pressure, total
cholesterol, smoking, DM, and diuretics therapy. In
addition, sex-specific analyses in the Framingham Heart
Study [8] revealed a strong and graded association
between baseline uric acid levels and an increased risk for
CAD, death from CV disease, and death from all causes
among women. This risk, however, was substantially
reduced after adjusting for age, and was eliminated
completely in the multivariate model. The NHANES I
epidemiologic study [12] also showed no association
between SUA and CV events in men; however, among
women, SUA was predictive of all-cause mortality and
ischemic heart disease. These associations persisted even
after excluding the first 10 years of follow-up and were
independent of antihypertensive agent and diuretics use,
diastolic blood pressure, obesity, and other characteristics.
The underlying mechanisms governing the higher
association of SUA with adverse events in women as
compared with men remain uncertain.
Nevertheless, several recent reports [5,6] have identified
epidemiologic evidence to support the contention that
SUA is an independent risk factor for hypertension-
associated morbidity and mortality. The third NHANES
[14] revealed that hypertensive people with SUA levels in
the second (5.0 to 5.9 mg/dL) and third quartiles (6.0 to
6.9 mg/dL) have a significantly higher relative risk (RR)
for both heart attack (RR = 1.32) and stroke (RR = 1.15).
Additionally, those in the fourth quartile (SUA > 7.0
mg/dL) were at substantially higher RR for heart attack
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SUA levels in the highest quartile (≥ 6.4 mg/dL) are
associated with an increased risk of CAD (OR, 1.88; 95%
CI, 0.91 to 3.84) as compared with the first quartile (< 4.8
mg/dL); however, this result was not significant (p = 0
.075). 
The mechanisms underlying SUA increases in patients
with atherosclerotic disease remain unknown. Laboratory
and clinical evidence suggests that SUA plays a role in
platelet adhesiveness [15], the formation of free radicals
[16], and oxidative stress [17]. Recently, several reports
[18,19] have linked SUA with MS, which is a cluster of
metabolic abnormalities, with insulin resistance as the
major characteristic. Since selective insulin resistance and
hyperinsulinism facilitates the active reabsorption of uric
acid [10], this concept may provide a physiological clue as
to why MS is closely linked to SUA. In the present study,
the only significant determinant of SUA levels in both men
and women was MS (p = 0.001, p = 0.039, respectively).
This result suggests that insulin resistance may be a
pathophysiologic mechanism of hyperuricemia in patients
with CAD. A trend was observed toward SUA being an
independent risk factor for CAD in women (p= 0.059, p=
0.062, respectively), but not in men (p= 0.423, p= 0.299,
respectively). 
The fact that SUA in the highest quartile showed an
increased risk of CAD, but the significance disappeared
after the multivariate regression analysis, suggests that the
influence of SUA on CHD is explained by the secondary
association of SUA with other established etiological risk
factors such HTN, dyslipidemia, hyperinsulinemia,
obesity, and MS. Regardless, SUA can used to predict
CAD as a high risk of vascular disease. 
The main limitation of the present study is that subjects
who were at higher risk of CAD as compared to a population-
based sample were assessed. As a consequence, a higher
percentage of DM and MS was observed (28.1%, 32.2%,
respectively) as compared to previous studies [6,20].
Therefore, caution is necessary when applying the results
of this study to different clinical settings.
Because we did not measure insulin resistance indices,
such as homeostasis model assessment (HOMA) insulin
resistance, we do not know if elevated SUA is related to
insulin resistance in this population. However, we may
assume the possibility of elevated SUA and increased
insulin resistance due to the strong relationship between
MS and insulin resistance. Nevertheless, the present study
has several potential strengths as compared with other
studies. We only enrolled subjects without a previous
history of taking diuretics or antihypertensive drugs,
which confounds the link between SUA and the risk of
CAD. Also, we identified the significant determinants
responsible for modulating SUA levels, thereby allowing a
basic understanding of why SUA is frequently elevated in
subjects at risk for CV. 
The present study demonstrates a strong association
between the severity of CAD and SUA levels in subjects
with suspected CAD. Nonetheless, SUA was not an
independent risk factor after adjusting for concomitant
CAD risk factors. The significant determinant of SUA
levels was MS, which is inextricably linked to insulin
resistance and is commonly associated with CAD. Therefore,
one can safely conclude that SUA may be merely a marker
of insulin resistance, which plays a causal role in the
pathogenesis of CAD.  
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